Anti-HA (12CA5)

Total Page:16

File Type:pdf, Size:1020Kb

Anti-HA (12CA5) For life science research only. Not for use in diagnostic procedures. Anti-HA (12CA5) Mouse monoclonal antibody (clone 12CA5) to a peptide epitope derived from the hemagglutinin protein of human influenza virus Cat. No. 11 583 816 001 200 ␮g (lyophilized) Cat. No. 11 666 606 001 5 mg (1 ml solution) y Version 07 Content version: April 2016 Store at Ϫ15 to Ϫ25°C 1. What this Product Does Purity The anti-HA monoclonal antibody is Ն 90% pure as determined by HPLC. Contents ␮ The antibody preparation does not contain pre- • Cat. No. 11 583 816 001: 200 g white lyophilizate servatives or stabilizers. • Cat. No. 11 666 606 001: 1 ml frozen liquid (5 mg/ml) 8 Affinity Ka = 1 × 10 /M Storage and Stability Isoelectric 6.4 If stored at Ϫ15 to Ϫ25°C, the lyophilized antibody preparations are Point stable until the expiration date printed on the label. For storage, prepare convenient aliquots and freeze them at Ϫ15 to 2. How to Use this Product Ϫ25°C. Avoid repeated freezing and thawing. 2.1 Before You Begin Lyophilized Anti-HA antibody is shipped at ambient temperature. Liquid Anti-HA antibody is shipped on dry ice. Epitope Tagging Before using Anti-HA to analyze the product of your target gene, Application incorporate the 27-base DNA sequence, which encodes the HA epi- tope, into the target gene sequence Anti-HA (12CA5) is used for the immunochemical detection of native using one of the following meth- influenza hemagglutinin protein and recombinant “epitope tagged” ods: proteins containing the HA epitope in western and dot blots, immuno- • Clone your gene of interest into a suitable bacterial or mammalian cytochemistry, and immunoprecipitation. expression vector. For experiments in which sensitivity is not critical, use Anti-HA • Prepare oligonucleotide linkers that can encode the HA epitope, (12CA5). For higher sensitivity detection in western blotting at 10- and clone the linkers into the target gene at the desired N-terminal, fold lower concentration use Anti-HA , High Affinity (3F10)*. C-terminal, or internal site (3). • Insert the HA-peptide coding sequence into the target gene by oli- Additional Equipment and Reagents Required gonucleotide-mediated site-directed mutagenesis (4,5). Additional equipment and reagents required to perform western blot analyses using Anti-HA (12CA5) include: Preparation of Working Solutions • Western blotting apparatus For the Iyophilized anti-HA preparation, prepare a concentrated stock • Western Transfer Buffer: 10% methanol, 24 mM Tris-base, 194 mM solution (0.4 mg/ml) by dissolving the entire Iyophilized anti-HA anti- ␮ ␮ glycine body (200 g) in 500 l PBS (rehydrate for 30 min prior to use). For storage, prepare convenient aliquots and freeze them at –15 to –25°C. • PVDF Western Blotting Membrane* The liquid anti-HA preparation (5 mg/ml) is ready to use as sup- • Washing Buffer (PBST): PBS, 0.05–2% Tween 20, pH 7.5 plied. • Blocking Solution (1:10 dilution of Western Blocking Reagent* in For most applications, dilute the Anti-HA antibody concentrate in an 1× PBST appropriate buffer to a concentration range of 0.1–5 ␮g/ml. Determine • secondary, POD-conjugated anti-mouse antibody (e.g., Goat Anti- optimal dilution buffer and dilution conditions for each specific appli- Mouse (H+L)-POD) cation and method. • Lumi-Light Western Blotting Substrate* or Lumi-LightPLUS Western Blotting Substrate* 2.2 Procedure • Lumi-Film Chemiluminescent Detection Film* Western Blotting Analysis To perform western blotting analysis using the anti-HA (12CA5), follow Product Characteristics the protocol below: Specificity Anti-HA recognizes the HA nonapeptide sequence Step Action YPYDVPDYA derived from the human influenza ³ ␮ virus hemagglutinin protein (amino acids 98-106) Perform western blot transfer to a PVDF membrane* (0.45 m (1). The antibody recognizes its antigenic determi- pore size) using Western Transfer Buffer. nant even when the HA peptide epitope is intro- The buffer must be at +2 to +8°C for electrophoretic trans- duced into unrelated recombinant proteins using a fer. technique known as “epitope tagging.” Clone 12CA5 (2) ␬ Subtype Mouse IgG2b 0416.05041112001 sigma-aldrich.com Step Action 3. Troubleshooting · Transfer the membrane (protein side up) to a container large enough to hold it. Problem Possible Cause Recommendation Be sure the side of the membrane that contains protein faces up so the detection reagents will have maximum Chemilumi- Poor isolation of Use a different cell lysis procedure access to the antigens. nescent or tagged protein chromo- A disposable, square petri dish (100 × 15 mm) makes a genic sig- Antibody too Double the concentration of the anti-HA convenient container for a 10 × 10 cm blot. nal weak or dilute and/or the secondary antibody) not visible » Too little protein Add more protein to gel. • After transfer, block the membrane for 1 hour at +15 to on the gel +25°C with 10 ml#) of Blocking Solution Poor transfer of • Increase the electrical current and/or the • Place container on a rotating platform and rotate gently for proteins from gel transfer time for the blot. 1 h at +15 to +25°C. to membrane • Be sure there are no air bubbles between the membrane and gel during transfer. Make sure the reagent completely and constantly covers the membrane during this incubation and all incubation Wrong type of For maximum signal, use PVDF membranes steps below. membrane for transfer. This incubation step may also be performed at +2 to +8°C Antibody incuba- Incubate anti-HA (and/or the secondary tion too short antibody) with the membrane blot for a lon- O/N. ger time. ¿ Drain the Blocking Solution from the container and wash the Signal develop- Double the development time. blocked membrane once with PBST. ment time too short ´ Dilute anti-HA antibody to a concentration of 0.1–1.0 ␮g/ml in Wash time too long • Shorten the washing time. a 1:20 dilution of Western Blocking Reagent in PBST. or too stringent • Omit Tween 20 from the Wash Buffer. Incubate membrane with diluted anti-HA antibody for 1 hour Enzyme on anti- Do not use sodium azide in any western blot at +15 to +25°C with gentle rotation. body conjugate reagent if you use POD-conjugated antibod- ² inactivated by ies. • Drain the antibody solution from the container and rinse the preservative membrane with approximately 20 ml#) of Wash Buffer. Substrate inactive Make fresh dilution of substrate or start with • Wash the membrane four times, 10 min per wash, with a different stock of substrate. #) 20 ml PBST. Epitope tag • Include protease inhibitors in lysis buffer. ¶ Dilute secondary, POD-conjugated antibody 1:10,000 in dilu- sequence is not • Use alternative expression system or opti- detectable due to: mize your expression system. ent (as in step 5 above) and incubate the membrane for 1 h at • Proteolytic cleav- • Insert multiple tag sequences into target +15 to +25°C with gentle rotation. age protein to increase avidity of antibody º Wash the membrane four times, 10 min per wash, with PBST. • Low level of reaction. expression • Use alternative insertion site within the tar- Prepare Lumi-Light Western Blotting Substrate* according to • Premature trans- get gene for the epitope tag sequence. package insert instructions. lation termina- ¾ tion resulting in • Drain the antibody solution from the container and rinse the loss of C-terminal membrane with approximately 20 ml#) of Wash Buffer. tag sequence • Wash the membrane four times, 10 min per wash, with High back- Antibody too con- Decrease concentration of anti-HA (and/or 20 ml#) PBST. ground, centrated Secondary Antibody) by half. additional µ Add the Lumi-Light reagent to the membrane. bands on Wash time too Wash time too short short ¸ Expose the membrane to X-ray film. For a 1 min substrate blot Incubation of Leave blot membrane in substrate for a development, perform a 1–5 min exposure initially. membrane with shorter time. The conditions for development and exposure may vary. substrate too long #) volume required per 100 cm2 membrane Wrong type mem- For minimum background, use PVDF mem- brane branes for transfer. Immunoprecipitation and immunoaffinity purification Blocking Reagent Use nonfat dry milk (5% w/v) dissolved in too dilute Reagent Diluent as Blocking Reagent. Anti-HA antibody is commonly used to isolate HA-tagged proteins and High concentrations of nonfat dry milk associated protein:protein binding partners by immunoprecipitation may reduce specific signal as well as (IP) or immunoaffinity purification. Numerous IP methods are found in background.) the literature (2, 3, 5). Optimal conditions for IP should be determined Contaminated • Use clean equipment, freshly prepared for each particular application. Use the Anti-HA Affinity Matrix (HA reagents or equip- • buffers, and new membranes. clone 3F10)* for the direct immunoprecipitation or purification of HA- ment • Always avoid touching membranes with tagged proteins. The high-affinity HA antibody is covalently coupled to bare hands; use gloves and forceps. agarose beads, which enables the rapid isolation of even rarely Secondary anti- Use an F(ab')2 fragment of a secondary anti- expressed HA-tagged protein with minimal interference of heavy- and body binds body, rather than an intact IgG. light-chain bands during western-blot analysis. untagged proteins. Heavy and light Use direct detection with peroxidase-conju- Immunofluorescence chains of primary gated monoclonal antibody to visualize Anti-HA antibody is commonly used to visualize HA-tagged fusion antibody visible on tagged proteins. proteins in various cell types by indirect immunofluorescence (6, 8-17). blot membrane For staining HA-tagged proteins in yeast, start with the method of Ber- Signal develop- Reduce development time by half. kower et al. (17). For staining of HA-tagged proteins in mammalian ment time too long cells, start with the method of Canfield and Levenson (11).
Recommended publications
  • A Conserved Influenza a Virus Nucleoprotein Code Controls Specific
    ARTICLE Received 8 Mar 2016 | Accepted 10 Aug 2016 | Published 21 Sep 2016 DOI: 10.1038/ncomms12861 OPEN A conserved influenza A virus nucleoprotein code controls specific viral genome packaging E´tori Aguiar Moreira1,2,3, Anna Weber1, Hardin Bolte1,2,3, Larissa Kolesnikova4, Sebastian Giese1, Seema Lakdawala5, Martin Beer6, Gert Zimmer7, Adolfo Garcı´a-Sastre8,9,10, Martin Schwemmle1 & Mindaugas Juozapaitis1 Packaging of the eight genomic RNA segments of influenza A viruses (IAV) into viral particles is coordinated by segment-specific packaging sequences. How the packaging signals regulate the specific incorporation of each RNA segment into virions and whether other viral or host factors are involved in this process is unknown. Here, we show that distinct amino acids of the viral nucleoprotein (NP) are required for packaging of specific RNA segments. This was determined by studying the NP of a bat influenza A-like virus, HL17NL10, in the context of a conventional IAV (SC35M). Replacement of conserved SC35M NP residues by those of HL17NL10 NP resulted in RNA packaging defective IAV. Surprisingly, substitution of these conserved SC35M amino acids with HL17NL10 NP residues led to IAV with altered packaging efficiencies for specific subsets of RNA segments. This suggests that NP harbours an amino acid code that dictates genome packaging into infectious virions. 1 Institute of Virology, University Medical Center Freiburg, 79104 Freiburg, Germany. 2 Spemann Graduate School of Biology and Medicine, University of Freiburg, 79104 Freiburg, Germany. 3 Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany. 4 Institute of Virology, Philipps-Universita¨t Marburg, 35043 Marburg, Germany. 5 Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15217, USA.
    [Show full text]
  • Dissecting Human Antibody Responses Against Influenza a Viruses and Antigenic Changes That Facilitate Immune Escape
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2018 Dissecting Human Antibody Responses Against Influenza A Viruses And Antigenic Changes That Facilitate Immune Escape Seth J. Zost University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons, Medical Immunology Commons, and the Virology Commons Recommended Citation Zost, Seth J., "Dissecting Human Antibody Responses Against Influenza A Viruses And Antigenic Changes That Facilitate Immune Escape" (2018). Publicly Accessible Penn Dissertations. 3211. https://repository.upenn.edu/edissertations/3211 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3211 For more information, please contact [email protected]. Dissecting Human Antibody Responses Against Influenza A Viruses And Antigenic Changes That Facilitate Immune Escape Abstract Influenza A viruses pose a serious threat to public health, and seasonal circulation of influenza viruses causes substantial morbidity and mortality. Influenza viruses continuously acquire substitutions in the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). These substitutions prevent the binding of pre-existing antibodies, allowing the virus to escape population immunity in a process known as antigenic drift. Due to antigenic drift, individuals can be repeatedly infected by antigenically distinct influenza strains over the course of their life. Antigenic drift undermines the effectiveness of our seasonal influenza accinesv and our vaccine strains must be updated on an annual basis due to antigenic changes. In order to understand antigenic drift it is essential to know the sites of antibody binding as well as the substitutions that facilitate viral escape from immunity.
    [Show full text]
  • Safety and Immunogenicity of a Baculovirus- Expressed Hemagglutinin Influenza Vaccine a Randomized Controlled Trial
    PRELIMINARY COMMUNICATION Safety and Immunogenicity of a Baculovirus- Expressed Hemagglutinin Influenza Vaccine A Randomized Controlled Trial John J. Treanor, MD Context A high priority in vaccine research is the development of influenza vaccines Gilbert M. Schiff, MD that do not use embryonated eggs as the substrate for vaccine production. Frederick G. Hayden, MD Objective To determine the dose-related safety, immunogenicity, and protective ef- ficacy of an experimental trivalent influenza virus hemagglutinin (rHA0) vaccine pro- Rebecca C. Brady, MD duced in insect cells using recombinant baculoviruses. C. Mhorag Hay, MD Design, Setting, and Participants Randomized, double-blind, placebo-controlled Anthony L. Meyer, BS clinical trial at 3 US academic medical centers during the 2004-2005 influenza season Jeanne Holden-Wiltse, MPH among 460 healthy adults without high-risk indications for influenza vaccine. Hua Liang, PhD Interventions Participants were randomly assigned to receive a single injection of saline placebo (n=154); 75 µg of an rHA0 vaccine containing 15 µg of hemagglutinin Adam Gilbert, PhD from influenza A/New Caledonia/20/99(H1N1) and influenza B/Jiangsu/10/03 virus Manon Cox, PhD and 45 µg of hemagglutinin from influenza A/Wyoming/3/03(H3N2) virus (n=153); or 135 µg of rHA0 containing 45 µg of hemagglutinin each from all 3 components LL CURRENTLY LICENSED IN- (n=153). Serum samples were taken before and 30 days following immunization. fluenza vaccines in the United Main Outcome Measures Primary safety end points were the rates and severity of States are produced in em- solicited and unsolicited adverse events. Primary immunogenicity end points were the bryonated hen’s eggs.
    [Show full text]
  • Biosafety Recommendations for Work with Influenza Viruses Containing a Hemagglutinin from the A/Goose/Guangdong/1/96 Lineage
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 62 / No. 6 June 28, 2013 Biosafety Recommendations for Work with Influenza Viruses Containing a Hemagglutinin from the A/goose/Guangdong/1/96 Lineage U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................2 Background .............................................................................................................2 Guidelines for Working with Influenza Viruses Containing an HA from the A/goose/Guangdong/1/96 Lineage ..................................3 Conclusion ...............................................................................................................6 References ...............................................................................................................7 Front cover photo: Transmission electron micrograph of avian influenza A H5N1 viruses (gold) grown in Madin-Darby canine kidney (MDCK) cells (green). The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR 2013;62(No. RR-#):[inclusive page numbers]. Centers for Disease Control and Prevention Thomas R. Frieden, MD, MPH, Director
    [Show full text]
  • Autocatalytic Activation of Influenza Hemagglutinin
    University of Pennsylvania ScholarlyCommons Department of Chemical & Biomolecular Departmental Papers (CBE) Engineering December 2006 Autocatalytic Activation of Influenza Hemagglutinin Jeong H. Lee University of Pennsylvania Mark Goulian University of Pennsylvania Eric T. Boder University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/cbe_papers Recommended Citation Lee, J. H., Goulian, M., & Boder, E. T. (2006). Autocatalytic Activation of Influenza Hemagglutinin. Retrieved from https://repository.upenn.edu/cbe_papers/83 Postprint version. Published in Journal of Molecular Biology, Volume 364, Issue 3, December 2006, pages 275-282. Publisher URL: http://dx.doi.org/10.1016/j.jmb.2006.09.015 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/cbe_papers/83 For more information, please contact [email protected]. Autocatalytic Activation of Influenza Hemagglutinin Abstract Enveloped viruses contain surface proteins that mediate fusion between the viral and target cell membranes following an activating stimulus. Acidic pH induces the influenza virus fusion protein hemagglutinin (HA) via irreversible refolding of a trimeric conformational state leading to exposure of hydrophobic fusion peptides on each trimer subunit. Herein, we show that cells expressing fowl plague virus HA demonstrate discrete switching behavior with respect to the HA conformational change. Partially activated states do not exist at the scale of the cell, activation of HA leads to aggregation of cell surface trimers, and newly synthesized HA refold spontaneously in the presence of previously activated HA. These observations imply a feedback mechanism involving self-catalyzed refolding of HA and thus suggest a mechanism similar to the autocatalytic refolding and aggregation of prions.
    [Show full text]
  • ACRONYM & GLOSSARY LIST - Revised 9/2008
    Survey & Certification Emergency Preparedness Initiative – All Hazards EMERGENCY PREPAREDNESS ACRONYM & GLOSSARY LIST - Revised 9/2008 ACRONYMS AAL Authorized Access List AAR After-Action Report ACE Army Corps of Engineers ACIP Advisory Committee on Immunization Practices ACL Access Control List ACLS Advanced Cardiac Life Support ACF Administration for Children and Families (HHS) ACS Alternate Care Site ADP Automated Data Processing AFE Annual Frequency Estimate AHRQ Agency for Healthcare Research and Quality (HHS) AIE Annual Impact Estimate AIS Automated Information System AISSP Automated Information Systems Security Program AMSC American Satellite Communications ANG Air National Guard ANSI American National Standards Institute AO Accrediting Organization AoA Administration on Aging (HHS) APE Assistant Secretary for Planning and Evaluation (HHS) APF Authorized Program Facility APHL Association of Public Health Laboratories ARC American Red Cross ARES Amateur Radio Emergency Service ARF Agency Request Form ARO Annualized Rate of Occurrence ASAM Assistant Secretary for Administration & Management (HHS) ASC Ambulatory Surgical Center ASC Accredited Standards Committee ASH Assistant Secretary for Health (HHS) ASL Assistant Secretary for Legislation (HHS) ASPA Assistant Secretary for Public Affairs (HHS) ASPE Assistant Secretary for Planning & Evaluation (HHS) ASPR Assistant Secretary for Preparedness & Response (HHS) ASRT Assistant Secretary for Resources & Technology (HHS) ATSDR Agency for Toxic Substances & Disease Registry (HHS) BARDA
    [Show full text]
  • Virology Techniques
    Chapter 5 - Lesson 4 Virology Techniques Introduction Virology is a field within microbiology that encom- passes the study of viruses and the diseases they cause. In the laboratory, viruses have served as useful tools to better understand cellular mechanisms. The purpose of this lesson is to provide a general overview of laboratory techniques used in the identification and study of viruses. A Brief History In the late 19th century the independent work of Dimitri Ivanofsky and Martinus Beijerinck marked the begin- This electron micrograph depicts an influenza virus ning of the field of virology. They showed that the agent particle or virion. CDC. responsible for causing a serious disease in tobacco plants, tobacco mosaic virus, was able to pass through filters known to retain bacteria and the filtrate was able to cause disease in new plants. In 1898, Friedrich Loef- fler and Paul Frosch applied the filtration criteria to a disease in cattle known as foot and mouth disease. The filtration criteria remained the standard method used to classify an agent as a virus for nearly 40 years until chemical and physical studies revealed the structural basis of viruses. These attributes have become the ba- sis of many techniques used in the field today. Background All organisms are affected by viruses because viruses are capable of infecting and causing disease in all liv- ing species. Viruses affect plants, humans, and ani- mals as well as bacteria. A virus that infects bacteria is known as a bacteriophage and is considered the Bacteriophage. CDC. Chapter 5 - Human Health: Real Life Example (Influenza) 1 most abundant biological entity on the planet.
    [Show full text]
  • Influenza Virus Hemagglutinin Stalk-Based Antibodies and Vaccines
    Available online at www.sciencedirect.com Influenza virus hemagglutinin stalk-based antibodies and vaccines 1 1,2 Florian Krammer and Peter Palese Antibodies against the conserved stalk domain of the activity and can readily be measured in serum using the hemagglutinin are currently being discussed as promising hemagglutination inhibition (HI) assay [3]. These anti- therapeutic tools against influenza virus infections. Because of bodies are directed against the membrane distal part of the the conservation of the stalk domain these antibodies are able to HA, the globular head domain (Figure 1a,b,d) [4,5,6 ], broadly neutralize a wide spectrum of influenza virus strains and which has a high plasticity and is subject to constant subtypes. Broadly protective vaccine candidates based on the antigenic drift driven by human herd immunity. There- epitopes of these antibodies, for example, chimeric and headless fore, antibodies that target this domain (HI-active anti- hemagglutinin structures, are currently under development and bodies) are very strain specific and quickly lose efficacy show promising results in animals models. These candidates against drifted strains. Because of this viral mechanism to could be developed into universal influenza virus vaccines that escape human herd immunity influenza virus vaccines protect from infection with drifted seasonal as well as novel have to be reformulated almost annually based on surveil- pandemic influenza virus strains therefore obviating the need for lance data from laboratories in the Northern and Southern annual vaccination, and enhancing our pandemic preparedness. hemispheres [7]. Vaccine strain prediction based on sur- Addresses veillance is a complicated and error prone process and 1 Department of Microbiology, Icahn School of Medicine at Mount Sinai, produces mismatches between circulating virus and New York, NY, USA vaccine strains from time to time which leads to a severe 2 Department of Medicine, Icahn School of Medicine at Mount Sinai, drop in efficacy of the seasonal influenza virus vaccines [8– New York, NY, USA 12].
    [Show full text]
  • Assembly of Influenza Hemagglutinin Trimers and Its Role in Intracellular Transport
    Assembly of Influenza Hemagglutinin Trimers and Its Role in Intracellular Transport Constance S. Copeland, Robert W. Doms, Eva M. Bolzau, Robert G. Webster,* and Ari Helenius Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510; * Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101. Abstract. The hemagglutinin (HA) of influenza virus posttranslational event, occurring with a half time of is a homotrimeric integral membrane glycoprotein. It ~7.5 min after completion of synthesis. Assembly oc- is cotranslationally inserted into the endoplasmic retic- curs in the endoplasmic reticulum, followed almost ulum as a precursor called HA0 and transported to the immediately by transport to the Golgi complex. A cell surface via the Golgi complex. We have, in this stabilization event in trimer structure occurs when study, investigated the kinetics and cellular location of HA0 leaves the Golgi complex or reaches the plasma the assembly reaction that results in HA0 trimer- membrane. Approximately 10% of the newly synthe- ization. Three independent criteria were used for de- sized HA0 formed aberrant trimers which were not termining the formation of quaternary structure: the transported from the endoplasmic reticulum to the appearance of an epitope recognized by trimer-specific Golgi complex or the plasma membrane. Taken to- monoclonal antibodies; the acquisition of trypsin resis- gether the results suggested that formation of correctly tance, a characteristic of trimers; and the formation of folded quaternary structure constitutes a key event stable complexes which cosedimented with the mature regulating the transport of the protein out of the en- HA0 trimer (9S20.w) in sucrose gradients containing doplasmic reticulum.
    [Show full text]
  • The Influenza Virus: Antigenic Composition and Immune Response
    Postgrad Med J: first published as 10.1136/pgmj.55.640.87 on 1 February 1979. Downloaded from Postgraduate Medical Journal (February 1979) 55, 87-97. The influenza virus: antigenic composition and immune response G. C. SCHILD B.Sc., Ph.D., F.I.Biol. Division of Viral Products, National Institute for Biological Standards and Control, Holly Hill, Hampstead, London NW3 6RB Summary capricious epidemiological behaviour of the The architecture and chemical composition of the causative virus and perhaps also the nature of the influenza virus particle is described with particular immune response in man to influenza antigens. reference to the protein constituents and their genetic control. The dominant role in infection of the surface Antigenic composition of the virus proteins - haemagglutinins and neuraminidases - Studies of the single-stranded, negative-strand, acting as antigens and undergoing variation in time RNA genome of the influenza A virus have revealed known as antigenic drift and shift is explained. The the existence of 8 species of RNA molecules (gene immuno-diffusion technique has illuminated the inter- segments) in the virus (McGeoch, Fellner and relationships of the haemagglutinins of influenza A Newton, 1976; Palese and Schulman, 1976a). viruses recovered over long periods of time. The Ho Each gene segment provides the code for one of the and H1 haemagglutinins are now regarded as a single 8 virus specific proteins synthetized in infected sub-type with H2 and H3 representing the haemag- cells. Seven of these proteins are integrated into glutinins of the 1957 and 1968 sub-types. Animal influenza virus particles. Table 1 summarizes the by copyright.
    [Show full text]
  • Hemagglutinin Immunoglobulin M (Igm) Monoclonal Antibody That Neutralizes Multiple Clades of Avian H5N1 Influenza a Virus Shuo Shen1, Geetha Mahadevappa1, Sunil K
    Journal of Antivirals & Antiretrovirals - Open Access www.omicsonline.org JAA/Vol.1 Issue.1 Research Article OPEN ACCESS Freely available online doi:10.4172/jaa.1000007 Hemagglutinin Immunoglobulin M (IgM) Monoclonal Antibody that Neutralizes Multiple Clades of Avian H5N1 Influenza A Virus Shuo Shen1, Geetha Mahadevappa1, Sunil K. Lal2 and Yee-Joo Tan1,3,* 1Collaborative Anti-viral Research Group, Institute of Molecular and Cell Biology, Singapore, 138673 2Virology Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Road, New Delhi 110067, India 3Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597 for novel antiviral therapy and vaccination strategies. The H5N1 Abstract viruses have now appeared in at least 53 countries on three continents The hemagglutinin (HA) of influenza A virus plays an and continue to evolve and diversify. Based upon the evolution of essential role in mediating the entry of the virus into host the HA gene, the H5N1 viruses could be grouped into numerous cells. In this study, 4 HA monoclonal antibodies (MAbs) clades, representing emerging lineages and multiple genotypes (see of immunoglobulin M (IgM) isotype were generated by recent review by (Guan et al., 2009)). This continuous evolution of using recombinant full-length HA protein, which was ex- the H5N1 virus, which is endemic in the poultry population of some pressed and purified from the baculovirus-insect cell sys- countries, poises a challenge to the development of vaccine or antiviral therapy that has to remain efficient against newly emerged tem, from a H5N1 isolate (A/chicken/hatay/2004(H5N1)). antigenic variants.
    [Show full text]
  • Presentation Outline
    Influenza Policy: The Impact of Epidemiology 2012 Trish M. Perl, MD, MSc Professor of Medicine, Pathology and Epidemiology Johns Hopkins University Senior Epidemiologist Johns Hopkins Health System Disclosures • Research support: VA and CDC (influenza prevention study), Merck, Sage • Advisory Boards: Pfizer, Hospira MMWR 2012; 61; 414 Overview • Epidemiology & Disease Burden • Impact on specific settings – Workforce – Healthcare setting • Options for prevention, control, & treatment, – Vaccination – Non-pharmacologic measures • Use of policy to impact vaccination in healthcare—rationale and issues Influenza .Acute respiratory illness - abrupt onset of symptoms – Spectrum of illness from asymptomatic to severe illness . Incidence: 5% to 20% of population, mortality 22,000-36,000 annually .23% HCW w/ serologic evidence of influenza – 59% recalled influenza like illness – 28% recalled respiratory infection .Nosocomial outbreaks documented and lead to morbidity for patients & staff, increased costs for institution - Attack rates of up to 54% reported - Mortality in NICUs up to 25% - HCWs are the primary vectors .Vectors for transmission include staff, visitors, patients Maltezou Scan Infect Dis 2010 online 1-9, Stott, Occup. Med. 2002; Talbot, ICHE 2005; Elder, BMJ 1996; Lester, ICHE 2003. Influenza Virus • Orthomyxovirus – Single stranded RNA virus Segmented HA (segmented genome) genome . Type A: NA – humans, animals, birds, more severe in the elderly . Type B: – humans only, more common in children . Type C: – uncommon in humans – 2 surface glycoproteins . Hemagglutinin (HA) Matrix M2 ion channel protein – attachment & entry protein . Neuraminidase (NA) – release Influenza A Virus Influenza Transmission to Humans Avian Avian virus virus Reassortment in humans Avian virus Human virus Reassortment in swine Epidemics, Pandemics & Antigenic Changes • Influenza viruses cause epidemics & pandemics – Size & relative impact result of .
    [Show full text]